TAS0612
TAS0612 is the orally active inhibitor of RSK、AKT and S6K. TAS0612 has antitumor activity[1].
Product Specifications
CAS Number
2148902-58-1
UNSPSC
12352005
Target
Akt; Apoptosis; Ribosomal S6 Kinase (RSK)
Type
Reference compound
Related Pathways
Apoptosis; MAPK/ERK Pathway; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tas0612.html
Purity
98.83
Solubility
DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C1NC2=NC=NC(N3CCC(CC3)C4=NC(C5=NN=C(C(F)(F)F)O5)=CC=C4NCCNC(C)(C)C)=C2C1(C)C
Molecular Formula
C27H34F3N9O2
Molecular Weight
573.61
References & Citations
[1]Koji Ichikawa, et al. TAS0612, a novel RSK, AKT, and S6K inhibitor, exhibits antitumor effects in preclinical tumor models. Mol Cancer Ther. 2023.|[2]Katsuragawa-Taminishi Y, et al., Triple targeting of RSK, AKT, and S6K as pivotal downstream effectors of PDPK1 by TAS0612 in B-cell lymphomas. Cancer Sci. 2023 Dec;114 (12) :4691-4705.|[3]Okamoto H, et al., Robust anti-myeloma effect of TAS0612, an RSK/AKT/S6K inhibitor, with venetoclax regardless of cytogenetic abnormalities. Leukemia. 2025 Jan;39 (1) :211-221.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
P70S6K
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC941631-500 1x 500 µL
CD9 (TSPAN29) (Motility-Related Protein-1) (CD9/1631), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details